Results 151 to 160 of about 339,891 (283)

New therapeutic options for metabolic‐associated steatotic liver disease

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
An increasing number of patients are being diagnosed with metabolic dysfunction‐associated steatotic liver disease (MASLD). MASLD results from disturbances in hepatic lipid metabolism and is associated with an increased risk of cirrhosis and hepatocellular carcinoma and significant extrahepatic morbidity, including cardiovascular disease and ...
Tessa Straatmijer, Midas Mulder
wiley   +1 more source

The infrequent association of synchronous renal and colonic malignancies.

open access: yesEuropean review for medical and pharmacological sciences, 1999
The coexistence of both kidney and colon primary malignancies is a rare condition. We report the case of a 75-year-old woman who presented with bilateral pulmonary nodules at chest X-ray and stratigraphy. Total-body CT scan showed multiple, apparently metastatic, bilateral pulmonary lesions, a diffusely dysomogeneous neoformation in the lower pole of ...
Amoroso, A   +7 more
openaire   +2 more sources

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

open access: yesBMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu   +5 more
wiley   +1 more source

Effects of multipath propagation delay on the uplink performance of synchronous DS-CDMA systems communicating in dispersive Rayleigh fading channels

open access: yes, 2004
The effect of the maximum asynchronous arrival time difference (AATD) of the delayed multipath components on the uplink performance of synchronous DS-CDMA systems is investigated, when communicating in a frequency-selective Rayleigh fading channel ...
Hwang, S-H., Hanzo, L.
core   +1 more source

Programmable three‐state nanoreactor for spatiotemporally controlled tumor therapy

open access: yesBMEMat, EarlyView.
The OMVs are shielded with a biocompatible Da–Ca shell, which prolongs its circulation period and promotes intratumoral accumulation. Importantly, the biocompatible Da–Ca shell can be controllably disintegrated in tumor microenvironment by using laser irradiation, generating in situ hyperthermia and releasing Ca2+.
Guihong Lu   +12 more
wiley   +1 more source

Endoscopic ultrasound in the staging of gastrointestinal luminal malignancies [PDF]

open access: yes, 2013
Endoscopic ultrasound (EUS) is an important tool in the staging of gastrointestinal cancers. This review highlights the use of EUS in the staging of gastrointestinal luminal malignancies and compares the performance of EUS with other imaging modalities ...
Azzopardi, Neville
core  

Tackling cancer stemness with nanotechnology in the era of precision medicine

open access: yesBMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo   +9 more
wiley   +1 more source

Glycosylated dendrimer nanoamplifiers hijack DNA damage‐immune crosstalk for enhanced dual‐track therapy of orthotopic glioblastoma

open access: yesBMEMat, EarlyView.
A glycosylated dendrimer nanoamplifier hijacks DNA damage‐immune crosstalk for enhanced radio‐immunotherapy of glioblastoma. The responsive release of demethylcantharidin simultaneously blocks repair‐mediated resistance by inhibiting DNA repair and overcomes adaptive immune resistance.
Cong Song   +10 more
wiley   +1 more source

Dual‐targeted nanomedicine delivering doxorubicin and nitric oxide for tumor immunomodulation and synergistic therapy

open access: yesBMEMat, EarlyView.
The mechanism of HA‐DS@PLGA nanoparticles co‐delivering DOX and SNAP (an NO donor) to suppress tumor growth, remodel the tumor microenvironment, and enhance antitumor immune responses for effective combinatorial cancer therapy. Abstract Cancer therapeutic efficacy is significantly influenced by tumor immunosuppressive environment possibly induced by ...
Xingzhou Peng   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy